参芪扶正注射液联合信迪利单抗对晚期胃癌化疗患者的增效减毒作用  

Synergistic and toxicity-reducing effects of Shenqi Fuzheng Injection combined with Sindilizumab on advanced gastric cancer patients undergoing chemotherapy

作　　者：谢媛媛[1] 邓亚男 许禹[2] 孙晓[1] XIE Yuan-yuan;DENG Ya-nan;XU Yu;SUN Xiao(Ward Ⅰ,Department of Gastroenterology,Nanyang Central Hospital,Nanyang 473000,Henan,CHINA;Department of CT Imaging Diagnosis,Nanyang Central Hospital,Nanyang 473000,Henan,CHINA)

机构地区：[1]南阳市中心医院消化内科一病区,河南南阳473000 [2]南阳市中心医院CT影像诊断科,河南南阳473000

出　　处：《海南医学》2024年第11期1549-1554,共6页Hainan Medical Journal

基　　金：2021年度河南省医学科技攻关计划联合共建项目(编号:LHGJ20211186)。

摘　　要：目的探讨参芪扶正注射液联合信迪利单抗对晚期胃癌化疗患者的增效和减毒作用。方法选取2022年8月至2023年6月南阳市中心医院收治的140例晚期胃癌化疗患者作为研究对象,采用随机数表法分为观察组70例、对照组70例。两组患者均予以FOLFOX6化疗,对照组患者同时予以信迪利单抗治疗,观察组患者则予以参芪扶正注射液联合信迪利单抗,以21 d为一个周期,连续治疗3个周期。治疗3个周期后比较两组患者的临床疗效和毒副反应发生率,同时比较两组患者治疗前后的血清肿瘤标志物[糖链抗原19-9(CA19-9)、糖链抗原125(CA125)、癌胚抗原(CEA)、糖链抗原72-4(CA72-4)]、免疫功能[CD3^(+)、CD4^(+)、免疫球蛋白A(IgA)、免疫球蛋白G(IgG)]和胃蛋白酶原水平(胃蛋白酶原Ⅰ、胃蛋白酶原Ⅱ)以及生存质量[卡氏行为状态(KPS)]。结果治疗3个周期后,观察组患者的客观缓解(ORR)率、疾病控制(DCR)率分别为64.29%、81.43%,明显高于对照组的45.71%、65.71%,而各项毒副反应发生率明显低于对照组,差异均有统计学意义(P<0.05);治疗3个周期后,观察组患者的血清CA19-9、CA125、CEA、CA72-4、胃蛋白酶原Ⅱ水平分别为(26.13±3.02)U/mL、(28.94±3.26)U/mL、(3.05±0.74)ng/mL、(5.46±1.03)U/mL、(12.07±1.05)ng/mL,明显低于对照组的(31.27±3.54)U/mL、(34.96±3.88)U/mL、(5.74±1.02)ng/mL、(8.12±1.34)U/mL、(15.69±1.78)ng/mL,差异均有统计学意义(P<0.05);与治疗前比较,观察组患者治疗1个周期、3个周期后的血清CD3^(+)、CD4^(+)、IgA、IgG水平明显高于对照组,差异均有统计学意义(P<0.05);观察组治疗1个周期、3个周期后血清胃蛋白酶原Ⅰ水平高于对照组,胃蛋白酶原Ⅱ水平明显低于对照组,差异有统计学意义(P<0.05);治疗3个周期后,观察组患者的生存质量总有效率为81.43%,明显高于对照组的58.57%,差异有统计学意义(P<0.05)。结论参芪扶正注射液联合信迪利单抗治疗晚�Objective To investigate the synergistic and toxicity-reducing effects of Shenqi Fuzheng Injection combined with Sindilizumab in patients undergoing chemotherapy for advanced gastric cancer.Methods A total of 140 patients with advanced gastric cancer undergoing chemotherapy were selected from Nanyang Central Hospital from August 2022 to June 2023 and randomly divided into an observation group of 70 patients and a control group of 70 patients using a random number table method.Both groups of patients were treated with FOLFOX6 chemotherapy.Patients in the control group were also treated with Sindilizumab,and those in the observation group were treated with Shenqi Fuzheng Injection combined with Sindilizumab,both continuously for 3 cycles,with 21 days as a cycle.After 3 cycles of treatment,the clinical efficacy and incidence of toxic side effects were compared between the two groups of patients,and the serum tumor markers[carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),carbohydrate antigen 72-4(CA72-4)],immune function[CD3^(+),CD4^(+),immunoglobulin A(IgA),immunoglobulin G(IgG)],and pepsinogen levels(pepsinogen Ⅰ,pepsinogen Ⅱ),as well as quality of life[Karnofsky Performance Status(KPS)]were compared before and after treatment between the two groups of patients.Results After 3 cycles of treatment,the objective response rate(ORR)and disease control rate(DCR)in the observation group were 64.29% and 81.43%,respectively,which were significantly higher than 45.71% and 65.71% in the control group;the incidence of toxic and side effects in the observation group was significantly lower than that in the control group;the differences were statistically significant(P<0.05).After 3 cycles of treatment,the levels of serum CA19-9,CA125,CEA,CA72-4,and pepsinogen Ⅱ in the observation group were(26.13±3.02)U/mL,(28.94±3.26)U/mL,(3.05±0.74)ng/mL,(5.46±1.03)U/mL,and(12.07±1.05)ng/mL,respectively,which were significantly lower than(31.27±3.54)U/mL,(34.96±3.88)U/mL,(5.74±1.02

关 键 词：胃癌 化疗 参芪扶正注射液 信迪利单抗 增效减毒 免疫功能 生存质量 

分 类 号：R735.2[医药卫生—肿瘤]